Showing 1 - 14 results of 14 for search 'Francesca Ligorio', query time: 0.04s Refine Results
  1. 1
    Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications

    Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications by Emma Zattarin, Rita Leporati, Francesca Ligorio, Riccardo Lobefaro, Andrea Vingiani, Giancarlo Pruneri, Claudio Vernieri

    Published 2020-12-01
    Get full text
    Article
  2. 2
    HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness

    HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness by Serenella M. Pupa, Francesca Ligorio, Valeria Cancila, Alma Franceschini, Claudio Tripodo, Claudio Vernieri, Lorenzo Castagnoli

    Published 2021-09-01
    Get full text
    Article
  3. 3
    Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin

    Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin by Emma Zattarin, Federico Nichetti, Francesca Ligorio, Francesca Ligorio, Laura Mazzeo, Riccardo Lobefaro, Giovanni Fucà, Giorgia Peverelli, Andrea Vingiani, Andrea Vingiani, Giulia V. Bianchi, Giuseppe Capri, Filippo de Braud, Filippo de Braud, Claudio Vernieri, Claudio Vernieri

    Published 2022-08-01
    Get full text
    Article
  4. 4
    Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications

    Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications by Francesca Ligorio, Luca Zambelli, Giovanni Fucà, Riccardo Lobefaro, Marzia Santamaria, Emma Zattarin, Filippo de Braud, Claudio Vernieri

    Published 2022-03-01
    Get full text
    Article
  5. 5
    Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications

    Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical impl... by Claudio Vernieri, Francesca Corti, Federico Nichetti, Francesca Ligorio, Sara Manglaviti, Emma Zattarin, Carmen G. Rea, Giuseppe Capri, Giulia V. Bianchi, Filippo de Braud

    Published 2020-04-01
    Get full text
    Article
  6. 6
    Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin

    Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin by Chiara Fabbroni, Giovanni Fucà, Francesca Ligorio, Elena Fumagalli, Marta Barisella, Paola Collini, Carlo Morosi, Alessandro Gronchi, Angelo Paolo Dei Tos, Paolo Giovanni Casali, Roberta Sanfilippo

    Published 2021-03-01
    Get full text
    Article
  7. 7
    The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab

    The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Tax... by Francesca Ligorio, Giovanni Fucà, Emma Zattarin, Riccardo Lobefaro, Luca Zambelli, Rita Leporati, Carmen Rea, Gabriella Mariani, Giulia V. Bianchi, Giuseppe Capri, Filippo de Braud, Claudio Vernieri

    Published 2021-04-01
    Get full text
    Article
  8. 8
    Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients

    Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients by Francesca Ligorio, Luca Zambelli, Achille Bottiglieri, Lorenzo Castagnoli, Emma Zattarin, Riccardo Lobefaro, Arianna Ottini, Andrea Vingiani, Serenella M. Pupa, Giulia V. Bianchi, Giuseppe Capri, Giancarlo Pruneri, Filippo de Braud, Claudio Vernieri

    Published 2021-04-01
    Get full text
    Article
  9. 9
    Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients

    Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients by Federico Nichetti, Francesca Ligorio, Emma Zattarin, Diego Signorelli, Arsela Prelaj, Claudia Proto, Giulia Galli, Antonio Marra, Giulia Apollonio, Luca Porcu, Filippo de Braud, Giuseppe Lo Russo, Roberto Ferrara, Marina Chiara Garassino

    Published 2019-12-01
    Get full text
    Article
  10. 10
    Antitumor activity and efficacy of shorter longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II–III HER2-negative breast cancer: a 10-year, retrospective analysis

    Antitumor activity and efficacy of shorter longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II–III HER2-negative breast cancer: a 10-year, retrospective a... by Riccardo Lobefaro, Emma Zattarin, Federico Nichetti, Michele Prisciandaro, Francesca Ligorio, Marta Brambilla, Pierangela Sepe, Francesca Corti, Giorgia Peverelli, Arianna Ottini, Teresa Beninato, Laura Mazzeo, Carmen G. Rea, Gabriella Mariani, Filippo de Braud, Giulia V. Bianchi, Claudio Vernieri, Giuseppe Capri

    Published 2020-12-01
    Get full text
    Article
  11. 11
    The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis

    The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrosp... by Leonardo Provenzano, Riccardo Lobefaro, Francesca Ligorio, Emma Zattarin, Luca Zambelli, Caterina Sposetti, Daniele Presti, Giulia Montelatici, Angela Ficchì, Antonia Martinetti, Alessio Arata, Marta Del Vecchio, Claudia Lauria Pantano, Barbara Formisano, Giulia Valeria Bianchi, Giuseppe Capri, Filippo de Braud, Claudio Vernieri, Giovanni Fucà

    Published 2023-04-01
    Get full text
    Article
  12. 12
    Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer

    Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cance... by Claudio Vernieri, Michele Prisciandaro, Federico Nichetti, Riccardo Lobefaro, Giorgia Peverelli, Francesca Ligorio, Emma Zattarin, Maria Silvia Cona, Pierangela Sepe, Francesca Corti, Sara Manglaviti, Marta Brambilla, Barbara Re, Antonino Belfiore, Giancarlo Pruneri, Luigi Celio, Gabriella Mariani, Giulia Valeria Bianchi, Licia Rivoltini, Giuseppe Capri, Filippo de Braud

    Published 2020-03-01
    Get full text
    Article
  13. 13
    Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors

    Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors by Emma Zattarin, Luigi Mariani, Alice Menichetti, Rita Leporati, Leonardo Provenzano, Francesca Ligorio, Giovanni Fucà, Riccardo Lobefaro, Luca Lalli, Andrea Vingiani, Federico Nichetti, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Chiara Corti, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi Di Mauro, Daniele Presti, Caterina Sposetti, Carlo Alberto Giorgi, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Daniele Generali, Giuseppe Curigliano, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri

    Published 2023-12-01
    Get full text
    Article
  14. 14
    Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors

    Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors by Emma Zattarin, Daniele Presti, Luigi Mariani, Caterina Sposetti, Rita Leporati, Alice Menichetti, Chiara Corti, Chiara Benvenuti, Giovanni Fucà, Riccardo Lobefaro, Francesca Ligorio, Leonardo Provenzano, Andrea Vingiani, Marta Del Vecchio, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi Di Mauro, Andrea Esposito, Carlo Alberto Giorgi, Luca Lalli, Laura Boldrini, Pier Paolo Berton Giacchetti, Ambra Carnevale Schianca, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Alberto Zambelli, Daniele Generali, Carmen Criscitiello, Giuseppe Curigliano, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri

    Published 2023-04-01
    Get full text
    Article

Search Tools: